Affirming support for most-favored-Nation drug pricing for United States patients.

[Congressional Bills 119th Congress]
[From the U.S. Government Publishing Office]
[H. Res. 928 Introduced in House (IH)]

<DOC>






119th CONGRESS
  1st Session
H. RES. 928

   Affirming support for most-favored-Nation drug pricing for United 
                            States patients.


_______________________________________________________________________


                    IN THE HOUSE OF REPRESENTATIVES

                            December 4, 2025

   Mrs. Dingell (for herself and Mr. Crane) submitted the following 
 resolution; which was referred to the Committee on Energy and Commerce

_______________________________________________________________________

                               RESOLUTION


 
   Affirming support for most-favored-Nation drug pricing for United 
                            States patients.

Whereas, according to a study conducted by the Department of Health and Human 
        Services Office of the Assistant Secretary for Planning and Evaluation 
        and RAND Health Care in 2024, the United States spends a higher and 
        growing share of total drug spending on new drugs compared to other 
        countries;
Whereas the United States prices across all drugs, both brand name and generic, 
        were nearly 2.78 times as high as prices in the comparison countries;
Whereas, on average, according to the Organization for Economic Cooperation and 
        Development, United States citizens spend over $1,400 on prescription 
        drugs every year, the highest per capita drug spending in the world;
Whereas, according to polling done by the Kaiser Family Foundation, 21 percent 
        of United States adults say they have not filled a prescription because 
        of the cost, 23 percent say they have instead opted for over-the-counter 
        alternatives, and 1 in 7 adults say they have cut pills in half or 
        skipped doses of medicine in the last year because of the cost;
Whereas lowering prescription drug prices to levels obtained in nations similar 
        to the United States has long enjoyed bipartisan support from Congress 
        and Presidential administrations;
Whereas, on May 12, 2025, President Trump signed an Executive order titled 
        ``Delivering Most-Favored-Nation Prescription Drug Pricing to American 
        Patients'' directing the Administration to take numerous actions to 
        bring United States drug prices in line with those paid by similar 
        nations;
Whereas, on July 31, 2025, President Trump sent letters to leading 
        pharmaceutical manufacturers outlining the steps they must take to bring 
        down the prices of prescription drugs in the United States to match the 
        lowest price offered in other developed nations; and
Whereas bipartisan Members of the 119th Congress have introduced legislation 
        that align with the goals of President Trump's May 12, 2025, Executive 
        order to align drug pricing for United States patients with the lowest 
        price offered in other developed nations: Now, therefore, be it
    Resolved, That the House of Representatives--
            (1) supports the idea that patients in the United States 
        should not be charged more than those in other countries for 
        the exact same prescription drugs;
            (2) recognizes and affirms the commitment of the United 
        States to reducing the cost of prescription drugs for all 
        United States citizens by--
                    (A) supporting policies that align the pricing of 
                drugs sold in the United States with that of other 
                developed nations; and
                    (B) supporting other available methods, including 
                expanding Medicare drug price negotiation and promoting 
                price competition in the drug market; and
            (3) supports the idea that United States citizens should 
        have access to high-quality, affordable prescription drugs.
                                 <all>